Fig. 1: BNT162b2 vaccine induces robust germinal center B cell and TFH cell response in mice.
From: Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
a, Experimental timeline and tests. FACS, fluorescence-activated cell sorting; ICS, intracellular cytokine staining. b, Serum anti-spike IgG, IgG1a and IgG2c binding titers (EC50) detected by ELISA. c, Pseudotyped lentivirus neutralization antibody titers (NT50) against SARS-CoV-2 WT and variants of concern (B.1.429, B.1.1.7, B.1.351, P.1 and B.1.617.2) measured at days 21 and 42. n = 10 mice per time point in b and c. d–f, GC B cell (d), TFH cell (e) and plasma cell (f) responses after BNT162b2 immunization. n = 11, 13, 16 and 10 for days 0, 7, 14 and 21, respectively. Data were combined from two or more independent experiments. One-way analysis of variance (ANOVA) followed by Tukey’s test was applied in b–f. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Differences between groups were considered significant for P values < 0.05. NS, not significant.
